Figure 2.

Proteomics reveals impairment of endo-lysosomal pathways in cells treated with UPCDC-30245 in HCT116 cells. (A) PCA revealed a separation between the treatment with DMSO and 5 of UPCDC-30245 for 6 h. (B) Volcano plot displaying the proteomic changes following UPCDC-30245 treatment in HCT116 cells, log₂ (fold change) indicates the logarithm to the base 2 of fold change, n = 3. (C) Functional enrichment analysis on proteins affected by UPCDC-30245. (D) Heatmap showing fold change in early endosome proteins, autophagy and lysosome related proteins which are significantly dysregulated by UPCDC-30245. (E) Enzymatic activity of HEXB and NAGLU. Cells indicates enzymatic activity was detected in HCT116 cells pre-treated with DMSO or 5 μM of UPCDC-30245 for 6 h. Lysate indicates enzymatic activity was detected using by treating HCT116 cell lysate with DMSO or 5 μM UPCDC-30245 for 30 min. An increase in enzyme activity was observed in the cells treated with UPCDC-30245, but not in the lysate, which indicates that UPCDC-30245 increased the amount of enzyme. N = 3. *, p < 0.05; **, p < 0.01; according to one-way ANOVA tests.